Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. permeability

PermeAbility SIGNED

PermeAbility - A non-invasive, side-effect-free diagnostic kit for intestinal disorders

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 PermeAbility project word cloud

Explore the words cloud of the PermeAbility project. It provides you a very rough idea of what is the project "PermeAbility" about.

normally    pain    causing    description    connected    risk    acute    surgeries    treatment    reinforced    economic    lgs    diagnosis    causes    solely    facts    unnecessary    bacteria    indirect    gut    diarrhea    mri    burden    markers    clinical    life    limited    assessing    stream    invasive    lesions    extensive    quality    waste    intestinal    diabetes    microcapsule    small    besides    diagnostic    evaluation    plasma    removal    barrier    particles    worldwide    though    syndrome    dramatic    leaky    cells    people    informed    qualitative    decision    compromise    35    patients    clear    performed    blood    threats    health    bowel    leak    poses    damage    lifetag    abdominal    toxic    heavy    food    digestion    inflammatory    rupture    disposing    urges    billion    diagnosed    stool    obesity    permeability    ibd    maintaining    articles    restricted    ulcers    tightly    arthritis    select    form    bleedings    symptoms    structure    direct    intestine    revealing    proprietary    inflammation    reported    organization    rheumatoid    compromises    biopsy    disease    wall    colonoscopy   

Project "PermeAbility" data sheet

The following table provides information about the project.

Coordinator		 LIEFTAG LDA 

Organization address
address: BIOCANT - ASSOCIACAO DE TRANSFERENCIA DE TECNOLOGI
city: CANTANHEDE
postcode: 3060 197
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Portugal [PT]
 Project website https://lifetag.pt
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-08-01   to  2019-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    LIEFTAG LDA PT (CANTANHEDE) coordinator 50˙000.00

Map

 Project objective

'Inflammatory Bowel Disease (IBD) is a form of acute inflammation to the small intestine that causes ulcers and extensive damage of the gut barrier causing it to rupture. This causes bleedings, abdominal pain, diarrhea, and a dramatic reduction of the quality of life. The intestinal barrier is normally a very well organised structure in which the cells are tightly connected maintaining the barrier. Moreover, IBD lesions compromise this intestinal organization and increases intestinal permeability, which is called leaky gut syndrome (LGS) being also a pre-disposing factor for several other health problems. LGS compromises digestion of food particles and removal of toxic waste products, and allows bacteria to 'leak' through the intestine to the blood stream. Besides in IBD, LGS is also common in people with health conditions such as obesity, rheumatoid arthritis and type 2 diabetes. Even though IBD poses significant threats to a patients’ health and a heavy direct and indirect economic burden, diagnosis of this condition is still limited assessing indirect parameters like general inflammation markers in plasma and stool and evaluation based by comparison on the patients symptoms description. The direct measures are also performed but are restricted to very invasive methods like biopsy or solely qualitative like MRI and microcapsule colonoscopy. In this way it is reported in several clinical articles a clear need for new diagnostic methods in IBD reinforced by facts like 35% of the performed surgeries for treatment revealing unnecessary and 1.9 billion people worldwide at risk for early lesions and IBD development not being diagnosed. In this way clinical practice urges for new methods for the assessment of lesions in the intestinal wall. Lifetag’s has developed PermeAbility, a new proprietary test to measure intestinal permeability to better select patients at high risk of IBD , leading to better informed clinical decision making, diagnosis, and treatment.'

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PERMEABILITY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PERMEABILITY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More  

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More  

MIGRATECH 4.0 (2019)

The revolution in micro-granulation technology for eco-friendly, production efficient, superior ceramic tiles

Read More